Ticker

Analyst Price Targets — AM

Page 1 • Showing up to 10
DateAnalystFirmTargetPrice @ PostSourceHeadline
July 14, 2026 9:45 amGoldman Sachs$24.00$22.46StreetInsider Antero Midstream Partners LP (AM) PT Raised to $24 at Goldman Sachs into earningsMember Login
February 24, 2026 10:54 amGoldman Sachs$23.00$21.70TheFly Antero Midstream price target raised to $23 from $18 at Goldman Sachs
December 23, 2025 11:10 amWells Fargo$20.00$17.63TheFly Antero Midstream price target raised to $20 from $19 at Wells Fargo
February 18, 2025 12:40 pmWells Fargo$17.00$16.67TheFly Antero Midstream price target raised to $17 from $16 at Wells Fargo
November 5, 2024 10:21 amJohn MackayGoldman Sachs$14.50$14.61StreetInsider Antero Midstream Partners LP (AM) PT Lowered to $14.50 at Goldman Sachs
October 24, 2023 9:05 amJohn MackayGoldman Sachs$12.50$12.25Benzinga Check Out 3 Energy Stocks With Over 6% Dividend Yields From Wall Street's Most Accurate Analysts
October 10, 2023 7:26 amJohn MackayGoldman Sachs$11.50$12.19Benzinga Check Out 3 High-Yielding Dividend Stocks In Energy Sector From Wall Street's Most Accurate Analysts
January 9, 2023 10:38 amMorgan Stanley$12.00$11.20Benzinga Morgan Stanley Maintains Underweight on Antero Midstream, Raises Price Target to $12
April 28, 2022 7:03 amWells Fargo$13.00$9.95Benzinga Wells Fargo Upgrades Antero Midstream to Overweight, Raises Price Target to $13

Latest News for AM

Carillon Eagle Mid Cap Growth Fund Q2 2026 Portfolio Review

Carillon Eagle Mid Cap Growth Fund stocks delivered solid results in the second quarter. Top securities in the quarter were Datadog, Marvell, Vertiv, Teradyne and Macom Technology Solutions. Top securities in the quarter were Datadog, Marvell, Vertiv, Teradyne and Macom Technology Solutions.

Seeking Alpha • Jul 14, 2026
Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg

Results from Study AM-001 mark a pivotal advance through the transition to a once daily lower 400mg dose of AM enabling: Production of GMP clinical batch for Galmed's upcoming clinical trials Solidification and prolongation of Aramchol's IP protection Potential reduction in drug CoGs by ~50% Improvement in patients' convenience and compliance upon potential commercialization RAMAT-GAN, Israel, May 14, 2026…

PRNewsWire • May 14, 2026
4 Dividend Energy Stocks to Buy in May

The energy sector is the top performer this year, but investors shouldn't forget the group's attractive dividend profile.

Fool - Investing News • May 11, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

Senate Trading Disclosures

NameTransaction DateTypeAssetAmountLink

House Trades Disclosures

NameTransaction DateTypeAssetAmountLink

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top